Lamellasome COVID-19

N/A

Report date: 2025/01/26 19:03:42
NME

Base Information

Drug NameLamellasome COVID-19
Drug Alias NameLamellasomes (Lamellar Biomedical)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, Adult
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLamellar Biomedical Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLamellar Biomedical Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, Adult
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A